Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06533722
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Study of the Efficacy and Safety of Adaptive Therapy for Metastatic Refractory Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer
Detailed Description:
This is a phase II prospective single arm clinical trial The objective of the study is to evaluate the efficacy and safety of adaptive therapy in the treatment of post-second-line advanced breast cancer The therapy regimen primarily including Gemcitabine Vinorelbine or Eribulin will be selected by the investigator based on current guidelines available treatments and an assessment of the patients clinical status preferences and financial situation This study plans to recruit 10 subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None